Revenues were $31,000 for the Q3 of 2022 $1,600,000 for the 9 months ended September 30, 2022. Revenue for 2022 versus related to a grant supporting the development of the HAV. Research and development expenses were $18,600,000 for the Q3 of 2023 compared to $17,300,000 for the Q3 of 2022 and were $56,400,000 for the 9 months ended September 30, 2023 compared to 40 $8,300,000 for the 9 months ended September 30, 2022. The current period increase is resulting primarily from personnel in external services to support expanded research and development initiatives and our clinical trials, including preparation for the HAV, trauma clinical trial end of completion and planned BLA filing for the vascular trauma indication and expansion of clinical development of HIV in AV Access for hemodialysis. General and administrative expenses were $6,100,000 for the Q3 of 2023 compared to $6,200,000 for the Q3 of 2022 we're $17,500,000 for the 9 months ended September 30, 2023 compared to $17,100,000 for the 9 months ended September 30, 2022, the increase during the 9 months ended September 30, 2023 compared to the prior year period resulted primarily from increased personnel costs, largely driven by preparation for the planned U.